海纳医药拟港股上市 中国证监会要求补充说明募集资金具体用途

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for 19 companies, including Haina Pharmaceutical, which is required to clarify the specific use of raised funds and the proportion of domestic and overseas uses [1][2]. Group 1: Regulatory Requirements - Haina Pharmaceutical must provide a legal opinion regarding the compliance of its capital reduction process, tax payments, and the payment of capital reduction consideration [1]. - The company is also required to verify historical shareholding arrangements in accordance with regulatory guidelines [1]. - The CSRC requests clarification on the compliance of Haina Pharmaceutical's establishment of overseas subsidiaries, including foreign investment and foreign exchange registration procedures [2]. Group 2: Business Operations - Haina Pharmaceutical's business scope includes "pharmaceutical development, research; medical research and experimental development; testing services," and the company must confirm whether it has the necessary qualifications and licenses [2]. - The company must disclose its involvement in third-party social insurance and housing fund payments, as well as the status of any ongoing litigation that may pose substantial obstacles to its overseas listing [2]. Group 3: Financial and Operational Insights - Haina Pharmaceutical is a comprehensive CXO service provider in drug research and manufacturing, ranking second in China for the total number of approved clinical trials and marketing licenses [3]. - The company operates one of the most comprehensive CXO platforms in the industry, covering the entire chain from drug discovery to commercial production [3]. - As of June 30, 2025, Haina Pharmaceutical has 398 ongoing CXO projects, showing a steady increase from 242 projects in 2022 and 331 in 2023 [3].